A
AEON Biopharma, Inc. (AEON)
ASE – Real Time Price. Currency in USD
1.16
+0.16 (16.00%)
At close: Mar 27, 2026, 4:00 PM EDT
1.10
-0.06 (-5.16%)
After-hours: Mar 27, 2026, 7:55 PM EDT
Get all premium features to the best stock analysis tool
ASE – Real Time Price. Currency in USD
1.16
+0.16 (16.00%)
At close: Mar 27, 2026, 4:00 PM EDT
1.10
-0.06 (-5.16%)
After-hours: Mar 27, 2026, 7:55 PM EDT
AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of chronic and episodic migraine, as well as develops ABP-450 for the treatment of gastroparesis and post-traumatic stress disorder. The company has license agreements Daewoong Pharmaceutical Co., LTD., and Viatris Inc. The company is based in Irvine, California.
| Name | Position |
|---|---|
| Dr. Chad K. Oh M.D. | Chief Medical Officer |
| Mr. Alex Wilson | Chief Legal and Strategy Officer & Corporate Secretary |
| Mr. Robert Bancroft | President, CEO & Director |
| Date | Type | Document |
|---|---|---|
| 2026-03-09 | 8-K | aeon-20260306x8k.htm |
| 2026-01-21 | 8-K | aeon-20260121x8k.htm |
| 2026-01-12 | 8-K | aeon-20260112x8k.htm |
| 2025-12-29 | DEF 14A | aeon-20251229xdef14a.htm |
| 2025-12-19 | PRE 14A | aeon-20251219xpre14a.htm |
| 2025-12-15 | 8-K | aeon-20251215x8k.htm |
| 2025-12-04 | 8-K | aeon-20251204x8k.htm |
| 2025-11-14 | DEFA14A | aeon-20231109xdefa14a.htm |
| 2025-11-13 | DEFA14A | aeon-20231109xdefa14a.htm |
| 2025-09-08 | 8-K | aeon-20250908x8k.htm |